ReviewFrontiers in bioengineering and biotechnology2021
CRISPR/Cas Technologies and Their Applications in
Review in Frontiers in bioengineering and biotechnology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Engineering the Gut Microbiome: Emerging Genome-Editing Strategies and Therapeutic Applications.Microorganisms · 2026Review
- Recent advances in metabolic engineering for microbial production of L-tyrosine.World journal of microbiology & biotechnology · 2026Review
- Diversity of CRISPR-Cas Systems Identified in UrologicalMicroorganisms · 2025Article
- High-throughput conjugation reveals strain specific recombination patterns enabling precise trait mapping in Escherichia coli.PLoS genetics · 2025Article
- Isolation, Identification, and Antibiotic Resistance, CRISPR System Analysis ofMicroorganisms · 2025Article
- Transcriptomic insights into slyA-mediated regulation of motility and secretion in Escherichia coli.Antonie van Leeuwenhoek · 2025Article
- Reviewing the complexities of bacterial biocide susceptibility and in vitro biocide adaptation methodologies.npj antimicrobials and resistance · 2025Review
- Engineering Useful Microbial Species for Pharmaceutical Applications.Microorganisms · 2025Review
- Modulating Microbial Materials - Engineering Bacterial Cellulose with Synthetic Biology.ACS synthetic biology · 2024Review
- CRISPR-Cas9-based genome-editing technologies in engineering bacteria for the production of plant-derived terpenoids.Engineering microbiology · 2024Review
- Advances and applications of CRISPR/Cas-mediated interference inEngineering microbiology · 2024Review
- OptimizingFrontiers in microbiology · 2024Review
- Multiplex gene knockout raises Ala-Gln production by Escherichia coli expressing amino acid ester acyltransferase.Applied microbiology and biotechnology · 2023Article
- Bioinformatic survey of CRISPR loci across 15 Serratia species.MicrobiologyOpen · 2023Article
- Bacterial-Artificial-Chromosome-Based Genome Editing Methods and the Applications in Herpesvirus Research.Microorganisms · 2023Review
- Striving for sustainable biosynthesis: discovery, diversification, and production of antimicrobial drugs in Escherichia coli.Biochemical Society transactions · 2022Review
- Past, Present, and Future of Genome Modification inMicroorganisms · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated protein (Cas) systems have revolutionized genome editing and greatly promoted the development of biotechnology. However, these systems unfortunately have not been developed and applied in bacteria as extensively as in eukaryotic organism. Here, the research progress on the most widely used CRISPR/Cas tools and their applications in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.